StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Madrigal Pharmaceuticals's cash was $838.75M at Jun 30, 2026. For fiscal 2025 it was $983.56M, up 5.6% from the year before. Over ten years it grew 30.9% a year on average. The highest annual figure on record is $983.56M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$983.56M+5.6%
FY2024Dec 31, 2024$931.25M+46.9%
FY2023Dec 31, 2023$634.13M+76.7%
FY2022Dec 31, 2022$358.77M+32.7%
FY2021Dec 31, 2021$270.35M-4.9%
FY2020Dec 31, 2020$284.15M-35.3%
FY2019Dec 31, 2019$439.05M-9.2%
FY2018Dec 31, 2018$483.72M+152.6%
FY2017Dec 31, 2017$191.53M+900.4%
FY2016Dec 31, 2016$19.15M-71.3%
FY2015Dec 31, 2015$66.60M-31.8%
FY2014Dec 31, 2014$97.70M+6.8%
FY2013Dec 31, 2013$91.50M-9.0%
FY2012Dec 31, 2012$100.60M+234.5%
FY2011Dec 31, 2011$30.08M-3.9%
FY2010Dec 31, 2010$31.31M-29.1%
FY2009Dec 31, 2009$44.16M-15.2%
FY2008Dec 31, 2008$52.05M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$838.75M+4.6%
Q1 FY2026Mar 31, 2026$812.77M-4.2%
Q4 FY2025Dec 31, 2025$983.56M+5.6%
Q3 FY2025Sep 30, 2025$1.11B+11.1%
Q2 FY2025Jun 30, 2025$802.02M-24.5%
Q1 FY2025Mar 31, 2025$848.07M-19.9%
Q4 FY2024Dec 31, 2024$931.25M+46.9%
Q3 FY2024Sep 30, 2024$1.00B+331.9%
Q2 FY2024Jun 30, 2024$1.06B+256.1%
Q1 FY2024Mar 31, 2024$1.06B+221.4%
Q4 FY2023Dec 31, 2023$634.13M+76.7%
Q3 FY2023Sep 30, 2023$232.35M+51.7%
Q2 FY2023Jun 30, 2023$298.42M+40.9%
Q1 FY2023Mar 31, 2023$329.48M+49.8%
Q4 FY2022Dec 31, 2022$358.77M+32.7%
Q3 FY2022Sep 30, 2022$153.20M-48.8%
Q2 FY2022Jun 30, 2022$211.77M-34.6%
Q1 FY2022Mar 31, 2022$219.95M-28.4%
Q4 FY2021Dec 31, 2021$270.35M-4.9%
Q3 FY2021Sep 30, 2021$299.14M-11.0%
Q2 FY2021Jun 30, 2021$323.85M-15.7%
Q1 FY2021Mar 31, 2021$307.22M-24.8%
Q4 FY2020Dec 31, 2020$284.15M-35.3%
Q3 FY2020Sep 30, 2020$335.94M-25.9%
Q2 FY2020Jun 30, 2020$384.38M-17.6%
Q1 FY2020Mar 31, 2020$408.51M-14.5%
Q4 FY2019Dec 31, 2019$439.05M-9.2%
Q3 FY2019Sep 30, 2019$453.61M-7.1%
Q2 FY2019Jun 30, 2019$466.40M-4.9%
Q1 FY2019Mar 31, 2019$477.83M+1153.3%
Q4 FY2018Dec 31, 2018$483.72M+152.6%
Q3 FY2018Sep 30, 2018$488.54M+3669.6%
Q2 FY2018Jun 30, 2018$490.31M+1309.0%
Q1 FY2018Mar 31, 2018$38.13M+364.1%
Q4 FY2017Dec 31, 2017$191.53M+900.4%
Q3 FY2017Sep 30, 2017$12.96M+54.4%
Q2 FY2017Jun 30, 2017$34.80M–
Q1 FY2017Mar 31, 2017$8.22M–
Q4 FY2016Dec 31, 2016$19.15M–
Q3 FY2016Sep 30, 2016$8.39M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?